Upon receipt of regulatory approval, Veloxis plans to launch and commercialize Envarsus® in the US through its own dedicated sales representatives and to commercialize the product in the rest of the world via partnering arrangements. The required infrastructure build for the US is underway and will be completed as the Company nears commercial launch. It is anticipated that a field sales force of approximately 20 representatives will be hired to call on the key transplant centres in the US.
The transplant marketplace in the US is ideally suited for a small and well-focused selling effort and the clinical practice of transplant medicine leads to a unique commercialization opportunity. Transplants are generally performed at a small number of highly specialized centres, of which there are approximately 250 in the entire US. Patients waiting for a transplant will often travel considerable distances for transplant at one of these few centres. As such, a limited number of sales representatives can cover the majority of the centres.
Veloxis has a partnership agreement with Chiesi in respect of the commercialization of Envarsus® in Europe, Turkey and CIS Countries. Chiesi has launched Envarsus® in several EU countries in 4Q 2014 and will continue to roll out launches through 2015 and beyond.